Table 1.
Association between FOXO3A expression and UTUC clinicopathological parameters.
| Parameter | Overall | FOXO3A (Low expression) | FOXO3A (High expression) | P-value |
|---|---|---|---|---|
| Patients (n) | 107 | 67 | 40 | |
| Age, years | ||||
| < 65 | 49 (45.8) | 30 (44.8) | 19 (47.5) | 0.842 |
| ≥ 65 | 58 (54.2) | 37 (55.2) | 21 (52.5) | |
| Gender | ||||
| Male | 71 (66.4) | 42 (62.7) | 29 (72.5) | 0.398 |
| Female | 36 (33.6) | 25 (37.3) | 11 (27.5) | |
| Multifocality | ||||
| Multifocal | 22 (20.6) | 12 (17.9) | 10 (25.0) | 0.460 |
| Single | 85 (79.4) | 55 (82.1) | 30 (75.0) | |
| Histologic grade | ||||
| Low | 37 (34.6) | 27 (40.3) | 10 (25.0) | 0.142 |
| High | 70 (65.4) | 40 (59.7) | 30 (75.0) | |
| pT stage | ||||
| Ta/T1 | 46 (43.0) | 23 (34.3) | 23 (57.5) | 0.026 |
| T2/T3/T4 | 61 (57.0) | 44 (65.7) | 17 (42.5) | |
| LNM | ||||
| No | 66 (61.7) | 36 (53.7) | 30 (75.0) | 0.040 |
| Yes | 41 (38.3) | 31 (46.3) | 10 (25.0) | |
| LVI | ||||
| Absent | 53 (49.5) | 23 (34.3) | 30 (75.0) | <0.001 |
| Present | 54 (50.5) | 44 (65.7) | 10 (25.0) | |
| Histological differentiation | ||||
| Pure urothelial | 89 (83.2) | 57 (85.1) | 32 (80.0) | 0.595 |
| Variant histology a |
18 (16.8) | 10 (14.9) | 8 (20.0) | |
| Adjuvant therapy | ||||
| Yes | 32 (29.9) | 25 (37.3) | 7 (17.5) | 0.048 |
| No | 75 (70.1) | 42 (62.7) | 33 (82.5) | |
| Neoadjuvant chemotherapy | ||||
| Yes | 15 (14.0) | 9 (13.4) | 6 (15.0) | 1.000 |
| No | 92 (86.0) | 58 (86.6) | 34 (85.0) |
LNM, lymph node metastasis; LVI, lymphovascular invasion; pT, pathological tumor stage.
a
Variant histology included micropapillary, plasmocytoid, sarcomatoid, and neuroendocrine types.